Table 4.
Comparison of Variables Between Eyes Under Continuous Treatment and Treatment Cessation
| At the Last Visit | During the Study Period | |||||
|---|---|---|---|---|---|---|
| Eyes Under Continuous Treatment (n = 74) | Eyes Under Treatment Cessation (n = 27) | P value | Not Achieved the Successful Cessation (n = 45) | Achieved the Successful Cessation (n = 56) | P value | |
| Age, year | 75.0 (9.1) | 72.7 (12.3) | 0.620* | 75.6 (8.8) | 73.4 (10.9) | 0.436* |
| Sex, No. (%) Men | 51 (68.9) | 16 (59.3) | 0.476† | 13 (28.9) | 21 (37.5) | 0.403† |
| Baseline BCVA, logMAR | 0.35 (0.34) | 0.59 (0.55) | 0.067* | 0.30 (0.31) | 0.51 (0.46) | 0.026* |
| Lesion size, mm2 | 6.4 (5.9) | 6.8 (7.1) | 0.820* | 7.0 (6.7) | 6.1 (5.9) | 0.341* |
| Lens status at baseline, No.(%), pseudophakia | 21 (28.4) | 6 (22.2) | 0.618† | 15 (33.3) | 12 (21.4) | 0.263 |
| Central retinal thickness at baseline, μm | 395.7 (192.8) | 376.4 (159.8) | 0.939* | 438.5 (219.2) | 352.0 (140.3) | 0.070* |
| Subfoveal choroidal thickness at baseline, μm | 212.6 (101.1) | 189.8 (101.9) | 0.380* | 202.2 (80.0) | 209.7 (112.9) | 0.809* |
| IRF at baseline, No. (%) | 17 (23.0) | 8 (29.6) | 0.329† | 10 (22.2) | 15 (26.8) | 0.649† |
| SRF at baseline, No. (%) | 62 (83.8) | 17 (63.0) | 0.032† | 37 (82.2) | 42 (75.0) | 0.470† |
| PED at baseline, No. (%) | 26 (35.1) | 12 (31.6) | 0.265† | 22 (48.9) | 16 (8.6) | 0.041† |
| Vitreoretinal adhesion at baseline, No. (%) | 16 (21.6) | 4 (14.8) | 0.325† | 12 (26.7) | 8 (14.3) | 0.138† |
| Subretinal hyperreflective material at baseline, No. (%) | 14 (18.9) | 11 (40.7) | 0.036† | 8 (17.8) | 17 (30.4) | 0.17† |
| Anti-VEGF agent used for loading phase, No. (%) aflibercept | 49 (66.2) | 14 (51.9) | 0.139† | 11 (24.4) | 27 (48.2) | 0.022† |
| Disease activity at 12 weeks, No. (%), absent | 39 (52.7) | 23 (85.2) | 0.002† | 20 (44.4) | 42 (75.0) | 0.002† |
| Number of recurrences during the study period | 3.9 (4.0) | 0.8 (1.3) | <0.001* | 4.5 (4.9) | 1.9 (1.9) | 0.002* |
| Follow-up period, months | 48.8 (27.2) | 53.0 (26.8) | 0.468* | 44.0 (26.8) | 54.4 (26.4) | 0.053* |
Notes: Data were presented as mean (SD) unless otherwise specified. *Mann–Whitney U-test. †Fisher’s exact test.
Abbreviations: BCVA, best corrected visual acuity; logMAR, logarithm of the minimum angle of resolution; IRF, intraretinal fluid; SRF, subretinal fluid; PED, pigment epithelial detachment; VEGF, vascular endothelial growth factor.